Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | 0.00% | -9.86% | -20.99% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 73.59M 101M |
---|---|---|---|---|---|
Net income 2024 * | -124M -169M | Net income 2025 * | -145M -198M | EV / Sales 2024 * | - |
Net cash position 2024 * | 254M 347M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-0.92
x | Employees | 66 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.9% |
Latest transcript on Athira Pharma, Inc.
1 week | -9.86% | ||
Current month | -29.93% | ||
1 month | -25.87% | ||
3 months | -37.86% | ||
6 months | +21.52% | ||
Current year | -20.99% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Litton
CEO | Chief Executive Officer | 56 | 19-07-10 |
Andrew Gengos
DFI | Director of Finance/CFO | 59 | 23-05-17 |
Rachel Lenington
COO | Chief Operating Officer | 51 | 21-06-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Grant Pickering
BRD | Director/Board Member | 56 | 22-01-26 |
John Fluke
BRD | Director/Board Member | 81 | 12-12-31 |
Joseph Edelman
BRD | Director/Board Member | 67 | 20-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +6.26% | - | |
0.00% | 147 M€ | +4.88% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.92 | 0.00% | 164,716 |
24-04-25 | 1.92 | -4.48% | 156,023 |
24-04-24 | 2.01 | -1.47% | 79,151 |
24-04-23 | 2.04 | -2.39% | 85,381 |
24-04-22 | 2.09 | -1.88% | 128,081 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.99% | 73.59M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ATHA Stock